The effect of 0.01% atropine and orthokeratology on ocular axial elongation for myopia children
A meta-analysis (a PRISMA-compliant article)
Yan Yu, MMa, Jiasu Liu, MMb,*

Abstract
Objectives This meta-analysis aimed to identify the therapeutic effect of 0.01% atropine with orthokeratology on ocular axial elongation for myopia children.

Methods We searched PubMed, Cochrane Library, and CBM databases from inception to July 1st, 2021. Meta-analysis was conducted using STATA version 14.0 and Review Manager version 5.3 softwares. We calculated the weighted mean differences to analyze the change of ocular axial length (AL) between orthokeratology combined with 0.01% atropine (OKA) and alone. The Cochran’s Q-statistic and I² test were used to evaluate potential heterogeneity between studies. To evaluate the influence of single studies on the overall estimate, a sensitivity analysis was performed. We also performed sub group and meta-regression analyses to investigate potential sources of heterogeneity. We conducted Begger funnel plots and Egger linear regression tests to investigate publication bias.

Results Nine studies that met all inclusion criteria were included in this meta-analysis. A total of 191 children in OKA group and 196 children in orthokeratology (OK) group were assessed. The pooled summary weighted mean differences of AL change was −0.55 (95% CI = −1.25−0.55) with statistical significance (t = −5.03, P < .01), which indicated there was obvious difference between OKA and OK in myopic children. Subgroup analysis also showed that OKA treatment resulted in significantly less axial elongation compared to OK treatment alone according to SER. We found no evidence for publication bias.

Conclusions Our meta-analysis indicates 0.01% atropine atropine is effective in slowing axial elongation in myopia children with orthokeratology.

Abbreviations: AL = axial length, OK = orthokeratology, OKA = orthokeratology combined with 0.01% atropine.

Keywords: atropine, meta-analysis, myopia, orthokeratology

1. Introduction
Myopia causes blurry vision when looking at distant object, which has become a worldwide healthy issue especially in some Asian areas.[1] There are about 1.406 billion myopia patients in the world, accounting for 22.9% of the total population. It is estimated that there will be 4.758 billion myopia patients by 2050, accounting for 49.8% of the total population.[2] Myopia brings not only the decline of vision, but also serious complications caused by high myopia that can lead to irreversible vision loss, such as glaucoma, cataract, retinal detachment, retinal atrophy and other eye diseases.[3] At present, the number of children with myopia is increasing rapidly, especially in recent decades. Children with myopia are showing an increasingly younger trend, thereby increase the risk of high myopia.[4] Therefore, it is urgent to explore appropriate treatment to control the progression of myopia in children.

Axial elongation is the main cause of myopia, therefore, controlling axial elongation is important to prevent high myopia.[5] Current measures for controlling the progression of myopia include wearing glasses, orthokeratology lens, low concentration atropine and behavioral intervention.[6] Atropine, as a nonselective M receptor antagonist, has been proved to have a significant control effect on the development of myopia.[7] One study used 0.5%, 0.1%, and 0.01% concentrations, which found that the higher the concentration, the more obvious the rebound, while the effect of 0.01% atropine on controlling the growth of myopia was sustained and stable.[8] There already has meta-

Editor: Jui-Yang Lai.

The authors have no funding and conflicts of interests to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information file].

a Ophthalmology Department of the First Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, China.

b Ophthalmology Department of the Second Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, China.

* Correspondence: Jiasu Liu, Ophthalmology Department of the Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province, China (e-mail: wyf027214@163.com, 8617709872606).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build upon the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Yu Y, Liu J. The effect of 0.01% atropine and orthokeratology on ocular axial elongation for myopia children: a meta-analysis (a PRISMA-compliant article). Medicine 2022;101:18(e29191).

Received: 22 November 2021 / Received in final form: 9 March 2022 / Accepted: 9 March 2022
http://dx.doi.org/10.1097/MD.00000000000029191
analysis proved that the effect of atropine in different concentrations on myopia.\textsuperscript{9} At present, 0.01\% atropine is considered to have good curative effect, less adverse reaction, more stable and less rebound than other concentrations of atropine after drug withdraw.\textsuperscript{10} Orthokeratology has been proved an effective means to control the progression of myopia in adolescents.\textsuperscript{11} The mechanism of controlling the progression of myopia is that the hydraulic pressure generated by the contact lens temporarily reshapes the cornea, aiming to correct the distant vision by changing the shape of the central cornea, and secondly, it makes the peripheral cornea steeper to make the image focus in front of the peripheral retina, reduce the refractive error, and then achieve the best corrected vision.\textsuperscript{12} Orthokeratology has a significant effect on the control of myopia progression, and has been accepted by doctors and patients.\textsuperscript{13} There are a small number of studies have shown that the combination of orthokeratology and atropine can enhance the effect of myopia control.\textsuperscript{14-16} However, due to individual differences, research groups, drug concentrations, and research design differences, the safety and effectiveness of the combined treatment still need to be verified. Therefore, the present meta-analysis aimed at determining the effect of 0.01\% atropine on ocular axial elongation for myopia children.

2. Methods

2.1. Literature search

We searched PubMed, Cochrane Library, and CBM databases from inception to July 1st, 2021. The following keywords and MeSH terms were used: [“orthokeratology”] and [“atropine”] and [“myopia”]. We also performed a manual search to find other potential articles.

2.2. Eligibility criteria

2.2.1. Type of study. This study included high quality randomized controlled trials, cohort studies and case-control studies.

2.2.2. Type of patients. The patients should be children aged younger than 18 years, who undergone myopia. We will not apply any restrictions of race, age, education background, and economic status.

2.2.3. Intervention and comparison. This study compared orthokeratology combined with 0.01\% atropine (OKA) with orthokeratology (OK) for myopia control.

2.2.4. Type of outcomes. The primary outcome was ocular axial elongation.

If the study did not meet all of these inclusion criteria, it was excluded. The most recent publication or the publication with the largest sample size was included when the authors published several studies using the same subjects.

2.3. Data extraction

Relevant data were systematically extracted from all included studies by 2 researchers using a standardized form.

![Flow chart of literature search and study selection. Nine studies were included in this meta-analysis.](image)

Figure 1. Flow chart of literature search and study selection. Nine studies were included in this meta-analysis.
researchers collected the following data: the first author’s surname, publication year, language of publication, study design, sample size, age, follow-up time, ocular axial length, instrument, SER and ocular axial elongation.

### 2.4. Quality assessment

The quality of the primary studies was assessed using the Cochrane risk of bias tool by 2 independent researchers and an additional investigator in the case of any conflicts. The risk of bias for each study was evaluated according to selection bias, performance bias, detection bias, attrition bias, reporting bias, and other sources of bias. Each of these biases were classified as high risk (score 0), low risk (score 2) and unclear risk of bias (score 1). The total risk of bias was calculated by a summation of all categories.

### 2.5. Statistical analysis

Review Manager 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) and STATA version 14.0 (Stata Corp, College Station, TX) softwares were used for the meta-analysis. We calculated the weighted mean differences with their 95% confidence intervals (CIs) to analyze the change of axial length between OKA and OK. The Cochran’s Q-statistic and I² test were used to evaluate potential heterogeneity between studies. If significant heterogeneity was detected (Q test $P < .05$ or $I^2$ test $> 50\%$), a random effects model was used or fixed effects model was used. To evaluate the influence of single studies on the overall estimate, a sensitivity analysis was performed. We also performed subgroup and meta-regression analyses to investigate potential sources of heterogeneity. We conducted Begger funnel plots and Egger linear regression tests to investigate publication bias.

### 3. Results

#### 3.1. Characteristics of included studies

Initially, the searched keywords identified 36 articles. We reviewed the titles and abstracts of all articles and excluded 12 articles; full texts and data integrity were also reviewed and 15 were further excluded. Finally, 9 studies that met all inclusion criteria were included in this meta-analysis. Figure 1 showed the selection process of eligible articles. A total of 191 children in OKA group and 196 children in OK group were assessed. We summarized the study characteristics in Table 1. Figures 2 and 3 represented the risk of bias in the primary studies based on the Cochrane risk of bias tool.

#### 3.2. Quantitative data synthesis

The random effects model was used due to obvious heterogeneity among the studies ($I^2 = 81.4\%$, $P < .01$). The pooled summary weighted mean differences of axial length (AL) change was $-0.90$ (95% CI $= -1.25$ to $-0.55$) with statistical significance ($t = -5.03$, $P < .001$), which indicated there was obvious difference between OKA and OK in myopic children (Fig. 4). Sensitivity analysis was carried out, and none of them caused obvious interference to the results of this meta-analysis (Fig. 5). Meta-regression analysis conducted based on language, follow-up time, AL measuring instrument and SER. The result found that SER could explain potential sources of heterogeneity (Table 2). Through the distribution characteristics of forest plot, SER = 3
was determined as the threshold, so subgroup analysis was performed according to whether SER was greater than 3. There was no significant heterogeneity within the group, but significant heterogeneity between the groups, which further explained that SER was the source of heterogeneity. The results of both groups showed that OKA treatment resulted in significantly less axial elongation compared to OK treatment alone (Fig. 4). We found no evidence of obvious asymmetry in the Begger funnel plots (Fig. 6). Egger test also did not display strong statistical evidence for publication bias.

3.3. Ethics and dissemination
We will not obtain ethic documents because this study will be conducted based on the data of published literature. We expect to publish this study on a peer-reviewed journal.

4. Discussion
As the most common type of ametropia, the prevalence of myopia is increasing year by year.²⁴ The degree of myopia will continue to increase with the age, which will seriously affect children’s normal life in the future.²⁵ As the loss of vision caused by high myopia is irreversible, myopia have become one of the main causes of untreated vision loss in the world.²⁶ The axis is an important monitoring index of myopia.²² When the axis elongated beyond the normal value, axial myopia is occurred. There is a parallel relationship between the length of the axis and the progression curve of myopia corresponding to age.²⁷ Atropine is an alkaloid derived from belladonna and is a nonselective muscarinic acetylcholine receptor antagonist. Atropine eye drops act on the antimuscarinic receptors of the retinal, choroid and sclera. It may increase choroidal thickness by regulating dopamine release, or it may regulate scleral fibroblasts interferes with sclera remodeling in myopia. The effect of atropine suppressing myopia progression is dose dependent²⁸ and is mainly based on its sustained impact on restraining changes in refraction, with lesser effect observed on inhibiting AL elongation.²⁹ It is still unrevealed which concentration and frequency of atropine have better control effect on myopia.³⁰ Some investigations showed that high-dose atropines showed better efficacy than moderate-dose and low-dose atropines but have more adverse effects.³¹ Some studies believe that 0.01% atropine has a certain positive effect in suppressing myopia.²¹–²³ and it is the most widely used concentration in clinic at present. Orthokeratology lens adopts reverse geometric design and is made of highly oxygen-
Figure 4. Overall and subgroup analysis forest plot of the effect of 0.01% atropine on ocular axial elongation for myopia children.

Figure 5. Sensitivity analysis. None of included studies caused obvious interference to the results of this meta-analysis.
permeable materials. By changing the shape of the central cornea, the refractive power is changed. Studied from various mechanisms have confirmed that wearing an orthokeratology is one of the effective ways to control the progression of myopia.\[32\] Therefore, the efficacy of the OK combined with 0.01% atropine in the treatment of myopic children is a problem worth studying in particular. At present, there is a lack of multi center and large sample research in this aspect. This study aims to provide a comprehensive and reliable conclusion on the effect of 0.01% atropine combined with OK on ocular axial elongation for myopia children.

In the present meta-analysis, the quality of the literature included is high, and the sensitivity analysis results are relatively stable. The deek funnel chart indicates that there is no obvious publication bias, indicating that the analysis results of this study are stable and reliable. Collectively, our findings strongly suggest that 0.01% atropine atropine is effective in slowing axial elongation in myopia children with orthokeratology. The possible reason is that the combined application of OK and atropine has a synergistic effect, and then the increase of pupil diameter enhances the amount of myopic defocus around the retina, so as to enhance the control effect of ocular axis.

Still, our study has certain limitations. First, owing to the relatively small sample sizes and low level of quality of the included studies, there was insufficient data, so well-designed multi-centre studies with large sample should be conducted. Moreover, the retrospective nature of a meta-analysis can lead to subject selection bias. Importantly, the majority of included studies originated from Asia, which may adversely affect the reliability and validity of our results. Thus, more researches should pay attention to the influence of ethnicity factors to avoid selection bias in the subsequent years.

5. Conclusion

Our meta-analysis suggests that 0.01% atropine and orthokeratology is effective in slowing axial elongation in myopia children. However, due to the limitations, further detailed studies that focused on the effect of different concentrations and administration frequencies of atropine combined with orthokeratology on myopia are required to confirm the present findings.

Acknowledgments

We would like to acknowledge the helpful comments on this paper received from our reviewers.

Author contributions

Conceptualization: Yan Yu.
Data curation: Yan Yu.
Formal analysis: Yan Yu.
Investigation: Yan Yu.
Methodology: Yan Yu.
Software: Jiasu Liu.
Supervision: Jiasu Liu.
Validation: Jiasu Liu.
Visualization: Jiasu Liu.
Writing – original draft: Jiasu Liu.
Writing – review & editing: Jiasu Liu.

Table 2

| Heterogeneity factors | Coefficient | SE  | t     | P    | UL  | LL  |
|-----------------------|-------------|-----|-------|------|-----|-----|
| Language              | 0.94        | 0.29| -0.19 | .86  | 0.40| 2.21|
| Follow-up time        | 0.96        | 0.19| -0.21 | .84  | 0.55| 1.68|
| Instrument            | 0.94        | 0.16| -0.39 | .72  | 0.58| 1.51|
| SER                   | 0.35        | 0.10| -3.74 | .02  | 0.16| 0.76|

95% CI = 95% confidence interval, LL = lower limit, SE = standard error, UL = upper limit.

Figure 6. Begger funnel plot of publication bias. No publication bias was detected in this meta-analysis.
References

[1] Walline JJ, Lindsley KB, Vedula SS, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev 2020;1:CD004916.

[2] Guo LY, Sun H, Hu M, et al. Mental health status of parents of young patients with high myopia. J Int Med Res 2020;48:30060519873474.

[3] Cooper J, Tkatchenko AV. A review of current concepts of the etiology and treatment of myopia. Eye Contact Lens 2018;44:231–47.

[4] Xiang ZY, Zou HD. Recent epidemiology study data of myopia. J Ophthalmol 2020;4:4395278.

[5] Shi YH, Li YG, Zhang JZ, et al. Observation on the effect of corneal plastic lens combined with 0.01% atropine eye drops on juvenile myopia. Chin J Pract Diagnosis Treat 2017;31:1290–9.

[6] Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: a meta-analysis. JAMA Ophthalmol 2017;135:624–30.

[7] Zhao SY, Zhang Y, Liu T, et al. Low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology 2020;127:910–9.

[8] Tan Q, Ng AL, Choy BN, et al. One-year results of 0.001% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt 2020;40:230–40.

[9] Chen Z, Zhou J, Xue F, et al. Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children. Br J Ophthalmol 2021;11:bjophthalmol-2020-317980.

[10] Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep 2020;10:12730.

[11] Kinoshita N, Konno Y, Hamada N, et al. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol 2018;62:544–53.

[12] Singh K, Bhattacharyya M, Goel A, et al. Orthokeratology in moderate myopia: a study of predictability and safety. J Ophthalmic Vis Res 2020;43:222–5.

[13] Pérez-González MJ, Peixoto-de-Matos SC, Faria-Ribeiro M, et al. Slowing the progression of myopia with contact lenses: a review. Eye Contact Lens 2018;44:231–47.

[14] Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens 2020;46:129–35.

[15] Wang SN, Wang L, Wang M. Combined orthokeratology and atropine for children with myopia: a meta-analysis. Ophthalmic Physiol Opt 2021;64:723–31.

[16] Guo C, Wan S, Zhang Y, Han J. The efficacy of atropine combined with orthokeratology in slowing axial elongation of myopia children: a meta-analysis. Eye Contact Lens 2021;47:98–103.

[17] VanTulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 2003;28:1290–9.

[18] Luo Y, Luo WQ, Lu PF, et al. Control effect of corneal plastic lens combined with 0.01% atropine eye drops on middle and low myopia in adolescents. Int J Ophthalmol 2021;14:47–52.

[19] Chen Z, Zhou J, Xue F, et al. Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children. Br J Ophthalmol 2021;11:bjophthalmol-2020-317980.

[20] Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep 2020;10:12730.

[21] Kinoshita N, Konno Y, Hamada N, et al. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol 2018;62:544–53.

[22] Tan Q, Ng AL, Choy BN, et al. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt 2020;40:357–66.

[23] Vincent SJ, Tan Q, Ng ALK, et al. Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control. Ophthalmic Physiol Opt 2020;40:728–37.

[24] Klaver C, Polling JR. Myopia management in the Netherlands. Ophthalmic Physiol Opt 2020;40:230–40.

[25] Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology 2020;127:910–9.

[26] Ruiz-Pomeda A, Villa-Collal C. Slowing the progression of myopia in children with the misight contact lens: a narrative review of the evidence. Ophthalmol Ther 2020;9:783–95.

[27] Han X, Guo X, Lee PY, et al. Six-year changes in refraction and related ocular biometric factors in an adult Chinese population. PLoS One 2017;12:e0183364.

[28] Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens 2020;46:129–35.

[29] Wang S, Wang J, Wang N. Combined orthokeratology with atropine for children with myopia: a meta-analysis. Ophthalmic Physiol Opt 2021;64:723–31.

[30] Gao C, Wang S, Zhang Y, Han J. The efficacy of atropine combined with orthokeratology in slowing axial elongation of myopia children: a meta-analysis. Eye Contact Lens 2021;47:98–103.

[31] Yang N, Bai J, Liu L. Low concentration atropine combined with orthokeratology in the treatment of axial elongation in children with myopia: a meta-analysis. Eur J Ophthalmol 2022;32:221–8.

[32] Lu W, Jin W. Clinical observations of the effect of orthokeratology in children with myopic anisometropia. Cont Lens Anterior Eye 2020;43:222–5.